Tag archive for ‘Copaxone’
Gordon Brown On Thursday, February 15th, 2018

Warren Buffett Boosts Teva With $358 Million Investment for 1.8%

  Teva shares rose 6% at the end of trading in New York after Berkshire Hathaway, the investment company controlled by Warren Buffett, revealed that it holds 18.9 million shares of Teva, which is 1.8% of the More...

Shai Genish On Thursday, October 26th, 2017

The UK Court Overturned Teva’s Copaxone Patent

  The British Supreme Court ruled Thursday in favor of Mylan and its Dutch partner Synthon, and canceled all Teva’s Copaxone for 40 mg in the country based on obviousness. A statement by Mylan believes More...

Teva Receives Approval to Market Copaxone in Japan

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) announced today that the the Japanese Ministry of Health, Labour and Welfare has approved once-daily Copaxone (glatiramer acetate injection) More...

Niva Goldberg On Tuesday, July 7th, 2015

Three Way Takeover Battle: Teva Plans Raising Mylan Bid to $43 Billion – Report

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), the Israeli drugmaker, is preparing to improved proposal for US rival Mylan to as much as $43 billion, $86 to $88 a share, as soon as this More...

Niva Goldberg On Thursday, June 18th, 2015

U.S. Court Invalidates Teva’s Copaxone Patent

The U.S. Court of Appeals has again ruled that Teva Pharmaceuticals Industries Ltd.’s patent for its top-selling multiple sclerosis treatment Copaxone is invalid. A Teva spokeswoman said that the company is “committed More...

Ilan Shavit On Monday, March 30th, 2015

Teva Buying Auspex for $3.5 Billion in Anticipation of Competition Over Copaxone

Read also: CEO Vigodman In Race To Save Teva Through ‘Inorganic Growth’ Just as JBN predicted (along with everybody else in the business) Teva Pharmaceutical Industries Ltd. Decided to buy a major generic drug More...

Shiri Habib-Valdhorn On Tuesday, January 27th, 2015

Teva Rivals Urge US Court to Expedite Copaxone Suit

Copaxone’s patent remains in force at least until the Federal Circuit Appeals Court reconsiders the case. The rivals of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) who are developing a generic More...

Globes On Monday, January 26th, 2015

Teva Gets First “Sell” Recommendation

Berenberg analysts see insurance companies pressuring MS patients to switch to generic versions of Copaxone. Last year, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) posted its highest return on More...

Nadav Neuman On Wednesday, January 21st, 2015

US Supreme Court Upholds Copaxone Patent

The ruling means Teva’s flagship multiple sclerosis treatment’s patent remains valid until September 2015.   The US Supreme Court has ruled in favor of Teva Pharmaceutical Industries Ltd. (NYSE: More...

OPKO
Shiri Habib-Valdhorn On Thursday, December 18th, 2014

Teva and Russian Partner at Loggerheads

– Relations between Teva and Biotec have deteriorated into a legal dispute and an entanglement with the Russian authorities. –   After years of successful partnership, relations between Teva More...

Email:

Delivered by FeedBurner